Monoclonal antibodies (mAbs) submitted to the workshop B cell panel were screened for reactivity with bovine surface immunoglobulin positive (SIg+) cells from tonsil, mesenteric lymph nodes (MLN), ileal Peyer's patches (IPP), thymus and peripheral blood by fluorescence activated cell sorter (FACS) analysis. All mAbs within B cell panel reacted with B cells except the negative control mAb VPM61. Although most mAbs stained the majority of B cells from different tissues, 14 mAbs did not stain B cells from IPP. Detailed FACS analysis of the 24 mAbs in preliminary clusters PC17, PC28, PC29, PC30, PC35, PC41 and PC43 showed all preliminary clusters (PC) to contain mAbs with similar and variable specificities. This absence of clear-cut clusters therefore did not permit a simple classification of B cell surface antigens via the B cell mAbs and suggests considerable complexity and variability of the B cell surface.

Oncology Letters

Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System

Article

作者: Tsukamoto, Taku ; Fujino, Takahiro ; Kaneko, Hiroto ; Uchiyama, Hitoji ; Hirakawa, Koichi ; Okamoto, Haruya ; Kawaji‑Kanayama, Yuka ; Uoshima, Nobuhiko ; Chinen, Shotaro ; Kawata, Eri ; Kuroda, Junya ; Inoue, Yu ; Mizutani, Shinsuke ; Kuwahara‑Ota, Saeko ; Miyashita, Akihiro ; Shimura, Yuji ; Nishiyama, Daichi ; Fuchida, Shin-Ichi

Azacitidine (AZA) has been one of the standard treatments for transplantation-ineligible patients with myelodysplastic syndrome (MDS); however, hematological toxicities frequently cause treatment interruption in the early phase of the therapy. The present study conducted a multicenter retrospective study to investigate the prognostic impacts of various factors, including factors included in the Revised International Prognostic Scoring System (IPSS-R) and severe cytopenia in the early phase of AZA monotherapy in 212 patients with MDS. Severe cytopenia was evaluated after the initiation of therapy by absolute neutrophil counts on the 29th day after AZA (ANC29) initiation, and red cell concentrates (RCC) and platelet concentrate (PC) transfusion units required within 28 days from the start of AZA, designated in the present study as RCC28 and PC28, respectively. The survival period was determined from the 29th day of AZA treatment to death from any cause as the conditional survival period after the first cycle of AZA (CS-AZA1). Multivariate analysis demonstrated that severe thrombocytopenia defined by >30 units of PC28 and very poor risk cytogenetics according to IPSS-R were independent prognostic factors for CS-AZA1. The Kyoto Conditional Survival Scoring System was subsequently developed by incorporating severe thrombocytopenia defined by PC28 and very poor risk cytogenetics, which successfully stratified the risks of the patients in CS-AZA1. In conclusion, extreme PC transfusion dependency during the first cycle of AZA and very poor risk cytogenetics are important prognostic factors in AZA monotherapy for MDS.

100 项与 PC28 相关的药物交易

登录后查看更多信息